Former FDA Commissioner Donald Kennedy: Lessons From A Different Era
Donald Kennedy has passed away after contracting COVID-19 in a nursing home. Even 40 years after he ran FDA, a remarkable number of themes of his tenure still resonate.
You may also be interested in...
Four ex-commissioners outline their ideas for reforming the Food & Drug Administration. They don't think new ideas are necessary: just follow through on their old favorites.
Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.
New drug pricing program under the Inflation Reduction Act could reduce the value of the 340B drug discount for safety net providers by as much as $1 billion in the first year, an analysis by the 340B Health association suggests.